However, amyloid plaque burden, which takes into account plaque numbers and size, was significantly lower after optogenetic treatment compared to light activation of mCherry (Fig. 3D; 1.43 ± 0.11% burden for mCherry vs. 1.01 ± 0.06% burden for ChR2; mCherry: n = 57 fields of view (FOV) in 8 APP mice; ChR2: n = 82 FOV in 10 APP mice; **P < 0.01). This evidence concerns the gene APP and amyloidosis.